Tectonic Posts Q3 Loss of $21.3M, Cash Runway Into Q1 2029, APEX Data Due January 2027
TECX sits 25% above its 52-week low of $15.52.
Summary
Tectonic reported a $21.3 million Q3 net loss and $234.7 million in cash, enough to fund operations into Q1 2029. The key near-term event is TX45 APEX Phase 2 topline data in PH-HFpEF, expected by the end of January 2027.
Key Events · Earnings and Guidance · TECX
-
Q3 Loss Widens on Higher R&D
Net loss was $21.3 million versus $19.0 million a year earlier. R&D rose to $17.4 million from $16.9 million, and G&A to $6.0 million from $5.0 million.
-
Cash Runway Into Q1 2029
Cash and equivalents stood at $234.7 million at September 30, 2026, up from $227.1 million at June 30, 2026, including about $22.3 million of net ATM proceeds raised in the quarter.
-
APEX Phase 2 Data Due January 2027
Topline results from the TX45 APEX Phase 2 trial in PH-HFpEF are expected by the end of January 2027. Enrollment completed in June 2026, and the IDMC recommended continuing without modification in July 2026.
-
TX2100 Trials Ramp Up
The TERRA Phase 1b trial in HHT is expected to start by year-end 2026 with interim data by year-end 2027, and the TIDAL Phase 2 trial in moderate-to-severe HHT in early 2027.
Analysis · TECX · Life Sciences
The quarter itself is unremarkable: R&D rose modestly to $17.4 million and the net loss widened to $21.3 million from $19.0 million a year ago. What matters is the balance sheet and the calendar. With $234.7 million of cash funding operations into Q1 2029, past both TX45 Phase 2 readouts, there is no near-term financing need. The single biggest swing factor for the stock is the APEX Phase 2 topline in PH-HFpEF, now guided to the end of January 2027, with ALPINE interim data in the second half of 2027 and TX2100's TERRA trial starting by year-end 2026.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TECX was trading at $19.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $379.6M. The 52-week trading range was $15.52 to $39.53. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.